All In Biotech

Drug Trial Radar · NCT07335198

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Mar 5, 2026

Primary completion

Aug 13, 2026

Study completion Aug 13, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

  • Efimosfermin alfaDrug

    Efimosfermin alfa to be administered

  • PlaceboDrug

    Placebo to be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs), treatment related AEs and serious adverse events (SAEs)Time frame: Up to 90 days
  2. Number of participants with clinically significant changes in hematology, chemistry and urinalysis parametersTime frame: Up to 90 days
  3. Number of participants with clinically significant changes in 12 Lead electrocardiogram (ECG)Time frame: Up to 90 days
  4. Number of participants with clinically significant changes in vital signsTime frame: Up to 90 days
  5. Area under the serum drug concentration versus time curve from time zero to the time of the last quantifiable concentration (AUC[0-t]) of efimosfermin alfaTime frame: Up to 90 days
  6. Area under the serum drug concentration versus time curve from time zero extrapolated to infinity (AUC[0-inf]) of efimosfermin alfaTime frame: Up to 90 days
  7. Maximum observed serum drug concentration, determined directly from the serum concentration-time data (Cmax) of efimosfermin alfaTime frame: Up to 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.